Doctors sometimes prescribe cheaper generic drugs instead of more expensive brand names.
医生有时开比较便宜的非注册商标的药品，而不开比较昂贵的品牌药。
Who pays the most for branded and generic drugs?
不论是品牌药还是非专利药，谁为药钱买单？
Rather, the key is to pitch branded generic drugs.
相反，关键是要瞄准有品牌的仿制药。
We all take heard and we all know back generic drugs.
我们都能把所听见的、我们都知道回来学名药。
GENERIC drugs are the scourge of the pharmaceutical industry.
非专利药品是医药产业的祸根。
Objective To introduce WHO's biowaiver policy for oral generic drugs.
目的介绍WHO关于口服仿制药生物等效豁免的相关政策。
We are working very hard to get generic drugs to people as soon as the law will allow.
在得到相关法律许可的同时，其实我们就已经开始非常努力地工作以获取仿制药。
If they're just doing generic drugs, just copies, that's not a real pharmaceutical industry.
如果他们只是生产仿制药，那只是在复制，不是一个真正的制药行业。
They encourage doctors to prescribe cheaper generic drugs instead of more expensive brand names.
他们鼓励医生给患者开较便宜的非专利药，而不是价格更高的品牌药。
First, the developed world. In 2010 rich countries will boost the fortunes of generic drugs in two ways.
首先在发达国家，2010年富裕国家将以两种方式促使仿制药增加财富。
There is also hope that two older generic drugs, amantadine and rimantadine, might be effective against bird flu.
金刚烷胺和金刚乙胺这两种较为古老的药物可能对于禽流感也是有一定效果的。
And yet the industry's salvation could very well lie in the embrace of that very same nemesis-generic drugs.
然而要拯救该行业，恰恰在于要去亲吻那道伤疤，即接受仿制药。
And that pharmaceutical companies should create high-quality generic drugs that won't break a family's budget.
制药公司应该生产高品质的无专利通用药品，以减轻病人家庭的经济负担。
You can check all the clinical studies for a variety of ailment and we tell you the best generic drugs that work.
你可以看到对许多疾病的临床研究，我们也会告诉你最佳的、有效的药物选择。
Pharmacy Generic drugs are viewed as a rare bright spot when it comes to the cost of the U. S. health-care system.
当谈到进入美国卫生保健制度的成本时，药业的仿制药被认为是罕见的亮点。
It was agreed that in an overwhelming public health emergency, poor countries would be allowed to produce generic drugs.
所达成的共识是，在来势凶猛的公众健康紧急情况下，贫穷国家将可以生产非专利药品。
The result will be increased competition in a generic drugs industry that is already struggling with tumbling prices.
这会加大仿制药企业间的竞争，而这个行业已经为暴跌的价格而争斗不休。
This is despite two significant exceptions: in pharmaceuticals, where the challengers have tended to make low-margin generic drugs;
有两个领域是例外：一是医药，“后起之秀”们偏向于制造低利润的非专利药；
This is a fascinating research from WHO that shows the effect of generic drugs on anti-retroviral drug compounds and cocktails.
一个世界卫生组织令人惊喜的研究展现了非专利药对治疗艾滋病的抗逆转录病毒复合药和鸡尾酒药的影响。
The sizeable profits they have made from generics also look as if they will peak, since 2006 is the biggest year for new generic drugs.
由于2006年是对新非专利药品最好的一年，从该类药品中取得的可观利润看上去也达到了顶点。
The industry is witnessing increased competition from generic drugs as an unprecedented number of branded medicines lose patent protection.
随着失去专利保护的品牌药物达到前所未有的数量，制药业面临的来自无商标药物的竞争日益激烈。
Generics firms will do better with biosimilars than they have with conventional generic drugs, insists Viren Mehta, an industry expert.
工业专家维伦梅塔表示，无专利保护制药公司制造生物仿制药品将会比制造传统的无专利保护药品更有优势。
Generics firms will do better with biosimilars than they have with conventional generic drugs, insists Viren Mehta, an industry expert.
工业专家维伦梅塔表示，无专利保护制药公司制造生物仿制药品将会比制造传统的无专利保护药品更有优势。
应用推荐